This is a summary of the European public assessment report (EPAR) for Rasilez. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rasilez.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension.
Therapeutic Area (MeSH)
ATC Code
C09XA02
ATC Item
aliskiren
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| aliskiren | N/A | 阿利吉仑 |
EMA Name
Rasilez
Medicine Name
Rasilez
Aliases
N/ANo risk management plan link.
